Related references
Note: Only part of the references are listed.Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma
Josep Malvehy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study
Eiji Kiyohara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer
Kazutoshi Fujita et al.
CANCER SCIENCE (2020)
Neutrophil plasticity in the tumor microenvironment
Morgan A. Giese et al.
BLOOD (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Review of Immune-Mediated Adverse Events in Melanoma
Lucy Boyce Kennedy et al.
ONCOLOGY AND THERAPY (2019)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guerin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
Jessica Da Gama Duarte et al.
FRONTIERS IN IMMUNOLOGY (2018)
Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study
Benjamin Weide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases
Mark B. Faries et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity
Chin Yang Chang et al.
ONCOTARGET (2016)
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Accumulation of Cytosolic Calcium Induces Necroptotic Cell Death in Human Neuroblastoma
Motonari Nomura et al.
CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles
Taeko Matsushima-Miyagi et al.
CLINICAL CANCER RESEARCH (2012)
The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma
E. Kiyohara et al.
GENE THERAPY (2012)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation
Atsuko Fujihara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells
Masayuki Kurooka et al.
CANCER RESEARCH (2007)
Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system
Y Kaneda et al.
MOLECULAR THERAPY (2002)
Share Paper
